Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income remains negative
Q3 FY2026 operating income was -$106.91M, compared with -$78.36M a year earlier. Trailing-twelve-month operating income was -$406.72M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 13 analysts of -$313.36M (+3.9%) for the fiscal year ending Dec 2026, a step up from the -63.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$106.91M-10.3% QoQ
- Last fiscal yearDec 2025
- -$326.2M-63.0% YoY
- LTMSep 2026
- -$406.72M-38.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -36.4% | +100.5% | +137.0 pp |
| 1 year | -63.0% | +3.9% | +66.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (326.2M) USD
- Year-over-year change
- -63.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (326.2M) | -63.0% |
| FY2024 | 2024-12-31 | (200.17M) | -58.4% |
| FY2023 | 2023-12-31 | (126.37M) | +41.2% |
| FY2022 | 2022-12-31 | (214.99M) | -28.5% |
| FY2021 | 2021-12-31 | (167.33M) | — |
Operating Income vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's LTM Sep 2026 operating income of -$406.72M is the 8th highest of the 10 companies compared; the peer median is -$122.21M.
- Its year-over-year change of -38.8% is the 8th highest of 10, against a peer median of -1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $881.2M | +60.2% | +35.5% | 23.8% | |
| LTM Sep 2026 | $122.33M | -49.2% | — | 10.2% | |
| LTM Dec 2025 | -$44.6M | +19.1% | — | — | |
| LTM Jun 2026 | -$111.81M | -274.3% | — | 13.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$122.21M | -31.3% | — | 611.0% |
| LTM Jun 2026 | -$188.54M | +17.6% | — | 24.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$223.08M | +18.7% | — | — |
| LTM Sep 2026 | -$406.72M | -38.8% | — | — | |
| LTM Sep 2026 | -$465.32M | -36.5% | — | — | |
| LTM Jun 2026 | -$542.7M | -1.7% | — | 15058.2% | |
| Peer median (excluding PRAX) | -$122.21M | -1.7% | +35.5% | 24.0% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.45M | 8.55M | 0 |
| Cost of Revenue | 0 | 154.44M | 86.77M | 152.41M | 140K |
| Gross Profit | 0 | (154.44M) | (84.32M) | (143.86M) | (140K) |
| Gross Margin | — | — | -3445.8% | -1682.0% | — |
| Research & Development | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
| Selling, General & Admin | 47.08M | 59.55M | 42.05M | 56.31M | 59.08M |
| Operating Expenses | 167.33M | 60.55M | 42.05M | 56.31M | 326.06M |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| EBITDA | (166.88M) | (213.57M) | (122.85M) | (182.46M) | (303.13M) |
| EBITDA Margin | — | — | -5020.2% | -2133.3% | — |
| Operating Income | (167.33M) | (214.99M) | (126.37M) | (200.17M) | (326.2M) |
| Operating Margin | — | — | -5164.4% | -2340.3% | — |
| Interest Income | 0 | 0 | 0 | 17.35M | 22.93M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 271K | 957K | 3.1M | 17.35M | 22.93M |
| Income Before Tax | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Pre-Tax Margin | — | — | -5037.9% | -2137.5% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Net Margin | — | — | -5037.9% | -2137.5% | — |
| EPS (Basic) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| EPS (Diluted) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| Weighted Avg Shares | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
| Weighted Avg Shares (Diluted) | 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.